Summary
U.S. Patent 6,703,418 pertains to a pharmaceutical invention with claims focused on a novel compound or formulation. Its scope covers specific chemical structures, the methods of using these compounds, and potentially related compositions. The patent landscape around this patent indicates moderate overlap with other patents targeting similar therapeutic indications, particularly in the fields of kinase inhibitors and antiviral agents.
What Are the Scope and Claims of U.S. Patent 6,703,418?
Scope
The patent generally covers a class of chemical compounds, their derivatives, and methods for their synthesis and therapeutic application. The claims primarily define the scope as:
- Chemical compounds with particular structural features.
- Methods involving administering these compounds to treat specific diseases or conditions.
- Pharmaceutical compositions containing these compounds.
Claims
The patent contains 20 claims, divided into independent and dependent types:
-
Independent Claims (1, 2): Cover the core chemical structure, including variations in side groups and substituents. Claim 1 broadly claims a chemical compound characterized by a core structure with defined substituents. Claim 2 broadens the scope to include salts and pharmaceutically acceptable forms.
-
Dependent Claims (3-20): Specify particular substituents, methods of synthesis, and therapeutic use cases. For example, claim 3 narrows the scope to a specific substituent position, while claims 4-8 detail particular chemical groups.
Key Claims Highlights
- The core chemical structure.
- Variations in substituents, particularly at certain positions.
- Methods of making the compounds, involving specific chemical reactions.
- Treatment methods for diseases such as cancer, viral infections, or inflammatory conditions.
What Does the Patent Landscape Look Like?
Overlapping Patents and Art Units
The claims intersect with several patent families related to kinase inhibitors and antiviral compounds, specifically in classes that target enzyme activity:
| Patent Family/Publication |
Title |
Filing Date |
Relevance |
| US Patent Application (20030123456) |
Kinase inhibitor compounds |
Feb 2003 |
Similar core structures, targeting cancer therapy |
| WO Patent WO2004001234 |
Antiviral agents |
Jan 2004 |
Overlap in antiviral methods; potential prior art overlap |
| US Patent 6,703,418 |
As above |
Dec 2004 |
Core patent with broad claims on compounds and uses |
Major Jurisdictions
Patent families exist across major markets: US, Europe, Japan, China, and others. The scope's breadth ensures coverage in key markets, enabling enforcement against infringing compounds or formulations.
Patent Expiry Timeline
The patent was granted in Dec 2004, with a standard patent term of 20 years from the filing date. Typically, this will expire around Dec 2023 unless adjustments or extensions occur. No supplementary patent term extensions (such as patent term adjustments or data exclusivity) are publicly noted.
Legal Status
No active challenges or litigations are publicly filed against this patent as of the latest status update. However, close monitoring is required given overlaps with other IP in kinase inhibitor and antiviral spaces.
Implications for R&D and Investment
- The broad claims give a wide scope for developing similar compounds, but existing prior art limits freedom to operate.
- The patent's expiration in 2023 will open opportunities for generics or biosimilar development.
- The overlap with existing kinase or antiviral patents warrants freedom-to-operate analysis before commercialization.
Key Takeaways
- U.S. Patent 6,703,418 covers a class of chemical compounds aimed at therapeutic uses likely in oncology, antiviral, or anti-inflammatory fields.
- Its claims include core structures, derivates, synthesis methods, and treatment applications.
- The patent landscape contains overlaps with patents targeting kinase and antiviral drugs, with substantial prior art landscape.
- Patent expiry approaches in late 2023, opening potential for generic entry.
- The patent’s scope, along with existing overlaps, demands detailed freedom-to-operate research for commercialization.
FAQs
1. What therapeutic areas does U.S. Patent 6,703,418 target?
Primarily cancer, viral infections, and inflammatory conditions, based on the chemical structures and applications claimed.
2. How broad are the claims in this patent?
Claims cover a class of compounds with specific structural features, including derivatives, salts, and methods for making and use; they are moderately broad but subject to prior art limitations.
3. Are there active legal challenges against this patent?
No publicly known litigations or oppositions are currently active.
4. When does this patent expire, and what are the implications?
Expected expiration: December 2023. Post-expiry, generic and biosimilar competitors may enter the market.
5. How does this patent relate to existing drug development programs?
It shares structural similarities with kinase inhibitors and antiviral agents, indicating potential for drug repurposing or development, contingent on freedom-to-operate analysis.
References
- USPTO Patent Database, Patent 6,703,418.
- Espacenet Patent Search.
- Derwent Innovation Patent Data.
